Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04549610
Other study ID # ULS2020.001
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date November 1, 2019
Est. completion date January 1, 2025

Study information

Verified date April 2024
Source Poznan University of Physical Education
Contact Guilherme G Artioli, Prof., PhD
Phone +55 11 3091-8783
Email artioli@usp.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims at assessing the influence of β-hydroxy-β-methylbutyrate (HMB) supplementation (4.0 g/day) supplemented for 7 days in a group of speed-strength trained individuals on lower-body strength performance, selected muscle histological, molecular and blood markers of muscle recovery in response to resistance exercise-induced muscle damage.


Description:

The main aim of the project is to assess the effects of seven days of HMB (4.0 g/day) or Placebo (PLA) supplementation on lower body strength performance, and functional, histological, clinical and molecular markers of muscle recovery after an acute resistance exercise session. The study is a double-blind, randomized, placebo-controlled, parallel trial. 30 male participants will be divided randomly into two parallel groups: One group receiving 4.0 g/day HMB and the second group receiving PLA. Supplementation period (HMB or PLA) will be seven days (five days before and two days after muscle damage induced by an acute resistance training session). Food intake during the intervention will be assessed with the use of a food diary. Before the start of the experimental protocol, the participants will be familiarized with all tests and procedures. During the first visit, participants will be assessed for their anthropometric characteristics, and baseline blood samples will be collected for the analysis of the activity of muscle damage markers [creatine kinase (CK) and lactate dehydrogenase (LDH)]. We will then carry out the evaluation of the maximal voluntary isometric contraction (MVIC; performed in a Biodex isokinetic dynamometer), lower body maximum dynamic strength (1RM) for squat, leg press, and leg extension exercises. The participants will then return to the laboratory to repeat the same tests and confirm the obtained results (MVIC and 1RM tests). On the third day, participants will take part in a resistance training session (RE3sets) to evaluate strength performance. We will monitor the maximum number of repetitions possible in three sets of three exercises (squats, the leg press, and leg extension), until the concentric failure, with a rest interval of two minutes per set. The workload will correspond to 80% of the individual's 1RM). Participants will then spend five to seven days without any leg strength/power training, in order to facilitate effective recovery prior to the next main resistance exercises training (RE5sets), which will be designed to induce muscle damage. Furthermore, HMB or PLA supplementation will commence five days before RE5sets, and continue for 48 hours after RE5sets. Before the RE5sets, a muscle biopsy will be done in the vastus lateralis for morphological analysis of the sarcomere integrity (histological analysis) and molecular testing (e.g. selected protein kinase activity (e.g. AKTser473, mTORSer2448, p70S7K1Thr389, 4E-BP1Ser65/Thr70, 4EBP1Thr37/46); muscle cholesterol, and mevalonate content). Blood samples will also be collected. After the biopsy, participants will carry out exercises similar to those performed in the preliminary studies, but will do 5 sets per exercise until concentric failure with a 2-min resting interval between sets and load corresponding to 80% of the participant's 1RM. 24 hours after the end of RE5sets, blood samples will be taken and the evaluation of the MVIC will be performed. 24 hours later (48 hours after the RE5sets), a muscle biopsy (for histological and molecular testing) will be conducted, and blood samples will be collected. Furthermore, the MVIC and RE3sets will also be measured. Collected data will be compared between groups and times using mixed models (proc mixed, SAS v.9.3) followed by multiple comparisons of a hypothesis-driven single degree of freedom contrast analysis. The sample size was estimated at 24 in total, assuming an intra- and inter-subject interaction model, alpha level of 5%, power (1-β) of 0.8 and effect size 0.3 (small) (G*Power v.3.9.1.2). We will recruit a slightly larger number of participants (n = 30) to allow for the likely dropouts that will occur throughout the study. The level of significance adopted will be p <0.05.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date January 1, 2025
Est. primary completion date December 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - written informed consent from all participants before the study - a current medical clearance to practice sports, - training experience: at least 1 year strength training programs that include lower limbs, - minimum of 3 workout sessions (strength/resistance training) a week, - protein intake in customary diet and during the study protocol > 1.6g / kg of body mass per day, - individual maximum strength greater than 2.5 times the body weight for the 1RM test in the leg-press. Exclusion Criteria: - current injury, - any health-related contraindication, - declared general feeling of being unwell, - unwilling to follow the study protocol, - serious disease or metabolic problems, - intake of creatine, caffeine or beta-alanine, or other ergogenic supplements 3 months before the beginning of the study, - history of anabolic androgenic steroids or drugs use that may interfere with muscle mass control (eg, corticosteroids), or affect physical performance, - smoking and tobacco use, - presence of infectious disease in the previous 4 weeks of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
HMB supplementation
Group taking oral HMB supplementation in a blinded capsule form.
Placebo treatment
Group taking oral supplementation with placebo (corn starch) in a blinded capsule form.

Locations

Country Name City State
Brazil Escola de Educação Física e Esporte da USP / School of Physical Education and Sport - USP. São Paulo São Paulo - SP

Sponsors (3)

Lead Sponsor Collaborator
Poznan University of Physical Education Escola de Educação Física e Esporte da Universidade de São Paulo (Brazil) - Parallel sponsor of the research, National Science Centre, Poland

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in the maximum voluntary isometric contraction (MVIC) after supplementation and exercises-induced muscle damage Maximum voluntary isometric contraction (MVIC) torque (Nm) Baseline, 24 hours and 48 hours after the end of exercises-induced muscle damage
Secondary Change in the histological sarcomere integrity (after biopsy of the vastus lateralis muscle samples) after supplementation and exercises-induced muscle damage The disruption of the Z-line areas and the total visible fiber area in muscle fibers (%) Baseline, 24 hours and 48 hours after the end of exercises-induced muscle damage
Secondary Change in the molecular potential (after biopsy of the vastus lateralis muscle samples) after supplementation and exercises-induced muscle damage AKTser473, mTORSer2448, p70S7K1Thr389, 4E-BP1Ser65/Thr70, and 4EBP1Thr37/46 kinase activity (optical density) Baseline, 24 hours and 48 hours after the end of exercises-induced muscle damage
Secondary Change in the muscle cholesterol and mevalonate content (in the vastus lateralis muscle samples) after supplementation and exercises-induced muscle damage Muscle cholesterol and mevalonate content (units) Baseline, 24 hours and 48 hours after the end of exercises-induced muscle damage
Secondary Changes in creatine kinase (CK) and lactate dehydrogenase (LDH) activity (IU) in blood after supplementation and exercises-induced muscle damage CK and LDH activity (IU) Baseline, 24 hours and 48 hours after the end of exercises-induced muscle damage
Secondary Change in the strength performance results (at 80% of the individual's 1RM) in three resistance exercises (squats, the leg press, and leg extension) before and after supplementation and exercises-induced muscle damage Number of repetitions in each sets of squats, the leg press, and leg extension (reps) Baseline and 48 hours after the end of exercises-induced muscle damage
See also
  Status Clinical Trial Phase
Completed NCT04136821 - The Long-term Effects of Oceanix™ on Resistance Training Adaptations N/A
Completed NCT03318731 - Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males N/A
Unknown status NCT02280668 - Investigating Muscle Repair in Response to Icing Therapy Post Eccentric Muscle Damage Exercise N/A
Recruiting NCT03766815 - Effect of Branched-chain Amino Acid Supplementation on Muscle Damage N/A
Completed NCT04315077 - The Short Term Effects of Oceanix Supplementation on Recovery N/A
Completed NCT03313388 - Tart Cherry Juice for Exercise Performance and Recovery N/A
Completed NCT03753321 - Whey and Soy Protein Supplementation in Football Players N/A
Recruiting NCT06334224 - Acute Physiological Responses to Twice Daily Blood Flow Restriction Training N/A
Recruiting NCT03707067 - Compression Garments for Recovery in Modern Pentathletes N/A
Completed NCT03707470 - Made to Measure Compression Garments for Recovery in Rugby Players N/A
Completed NCT05037942 - The Effects of Restriction Pressure on Muscle Damage Responses to Blood Flow Restriction Exercise N/A
Completed NCT05100459 - The Effects of Whey Protein Supplements on Markers of Exercise-induced Muscle Damage in Resistance-trained Individuals N/A
Completed NCT05804604 - Bone Intake Proteins and Muscle Mass Deficiency in Proximal Femur Fractures
Completed NCT05011643 - Exercise-induced Muscle Damage in Statin Users
Completed NCT01827696 - Effect of American Ginseng on Exercise-induced Muscle Soreness Phase 1
Completed NCT01728675 - Eccentric Exercise and Oxidative Stress N/A
Completed NCT03527797 - Diaphragm Protective Ventilation in the Intensive Care Unit N/A
Withdrawn NCT05044936 - Topical Cannabidiol Cream and Post-exercise Recovery Early Phase 1
Completed NCT04679519 - The Effects of Protein Supplementation in Females and Males Following Acute Eccentric Exercise N/A
Completed NCT01555775 - Compared Effect of a Fruit Milk Shake With a Protein-Carbohydrate Supplement on Recovery After Resistance Exercise N/A